Legend Biotech Spotlights Solid Tumor CAR-T Advances and Expanded Clinical Data at ASCO 2026

ASCO 2026 Focuses on Next-Gen Therapies for Difficult Cancers

Legend Biotech (NASDAQ: LEGN) is set to unveil new clinical insights at the 2026 American Society of Clinical Oncology meeting, particularly early results from its investigational CAR-T therapy, LB2102, signaling meaningful progress in the treatment landscape for solid tumors such as small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC).

LB2102: Early Data on an Investigational Solid Tumor CAR-T

The highlight is a rapid oral presentation summarizing preliminary Phase 1 study results for LB2102, a chimeric antigen receptor T-cell (CAR-T) therapy that targets DLL3, a protein highly expressed in certain aggressive lung cancers. Early findings demonstrate manageable safety and clinical activity, reinforcing the possibility of moving CAR-T therapies beyond blood cancers into solid malignancies—a key milestone for Legend Biotech's pipeline and for the field at large.

LB2102, currently being evaluated in the United States, is part of a global agreement with Novartis, with Legend overseeing ongoing clinical trials and Novartis leading further development and commercialization worldwide. This strategic partnership underlines industry commitment to unlocking CAR-T therapies for broader patient populations.

CARVYKTI Continues to Show Clinical Depth in Multiple Myeloma

Legend Biotech will also present new data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), its FDA-approved, BCMA-directed CAR-T cell therapy for patients with relapsed or refractory multiple myeloma. Highlights include:

• A poster featuring a subgroup analysis from the Phase 3 CARTITUDE-4 trial, examining outcomes among patients who responded well to bridging therapy based on their cytogenetic risk.
• An additional poster on immune effector cell-associated enterocolitis (IEC-EC) incidence, drawing from real-world and clinical study experiences.

To date, CARVYKTI is the only BCMA-targeted CAR-T cell therapy approved for use after one prior therapy in multiple myeloma, with commercial availability spanning 18 countries and more than 10,000 patients treated globally—a rare milestone in cell therapy adoption.

Key ASCO 2026 Presentations at a Glance

CARVYKTI Safety: Detailed Real-World Data and Remaining Risks

While CARVYKTI’s efficacy in relapsed or refractory multiple myeloma is well-established, Legend Biotech's safety profile reporting remains critical. Of 285 patients across pivotal trials:

• Cytokine Release Syndrome (CRS) occurred in 84%, with 4% experiencing severe reactions.
• Neurologic toxicities presented in 24% of treated patients, including 13% with ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome).
• 57% had infections post-infusion, 24% of which were severe (Grade 3 or above); COVID-19 was a factor in several fatal infections.
• Secondary malignancies—mainly myeloid neoplasms—occurred in 5% of treated patients, with a median onset at 447 days post-infusion.

Supportive care protocols, close patient monitoring, and institutional management guidelines are emphasized to help mitigate these risks and optimize outcomes for eligible patients.

Expanding the Reach of Cell Therapy

Legend Biotech’s latest ASCO showcase reflects its dual commitment: driving innovation in relatively untapped areas such as solid tumors, and steadily building evidence and accessibility for approved therapies in blood cancers. The presentations will be complemented by an on-site investor event on May 31, exploring how these approaches are shaping the future of cancer therapy.

Looking Ahead: Strategic Partnerships and Pipeline Growth

Ongoing collaborations with leading pharmaceutical companies, including the Novartis agreement for DLL3-targeted CAR-Ts and the Johnson & Johnson collaboration on CARVYKTI, position Legend Biotech as a major player in advancing cell therapy solutions. Continued clinical momentum and regulatory milestones are likely to remain watch points for investors, clinicians, and patients alike as 2026 unfolds.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI